Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings ...

Jason Kelly, Founder, CEO & Director, emphasized Ginkgo’s mission to "make biology easier to engineer" and outlined three major objectives heading into 2026: delivering robotics and software for ...

OpenAI’s GPT can summarize research papers and make predictions—but can it do science? Can it generate hypotheses, design experiments, interpret results and iterate? Last summer researchers at OpenAI ...

Ginkgo Bioworks reported solid Q3 results, but underlying performance was weaker than the financials suggest after accounting for meaningless non-cash revenue. Ginkgo's new business model focuses on ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) stands against other best ...

The average one-year price target for Ginkgo Bioworks Holdings (NYSE:DNA) has been revised to $10.88 / share. This is a decrease of 11.11% from the prior estimate of $12.24 dated November 7, 2025. The ...

The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc.

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago.

Ginkgo Bioworks Holdings (NYSE:DNA) is preparing to release its quarterly earnings on Thursday, 2026-02-26. Here's a brief overview of what investors should keep in mind before the announcement.

View Ginkgo Bioworks Holdings, Inc. Class A DNA stock quote prices, financial information, real-time forecasts, and company news from CNN.